Value
5.0/10data confidence 40%| Component | Sub-score |
|---|---|
| P/S | 6.7 |
| EV/EBITDA | 3.4 |
UHT · Why this verdict
Why Universal Health Realty Income (UHT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.1/10
ConfidenceHIGH
MacroRISK_OFF
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality is high at 7.5 out of 10, with 19% margins, free cash flow at 239% of net income and a Piotroski F-Score of 8/9. Quality breakdown | Piotroski F-Score holds at 7 or higher and cash conversion stays above 100%. | ↓Deteriorating |
| CounterREIT cash flow metrics ignore heavy depreciation and recurring capital spending, and high leverage (D/E 2.7) reduces the margin for error. | ||
The price of $37.67 is 0.7% above the $37.40 analyst target, leaving no analyst-implied upside against 5.1% downside. Targets | Analysts raise the target above $41, restoring at least 10% of upside. | ↓Deteriorating |
| CounterTargets for REITs tend to follow price, so a new higher target may come only after the stock has already moved up. | ||
A leverage penalty applies at a debt-to-equity of 2.7, and the dividend is flagged as a high-yield-but-unsafe yield trap. Bear case | Debt-to-equity falls below 2.0 and the dividend is held flat or raised. | →Stable |
| CounterHealthcare REIT leases are long-dated and stable, so leverage may be sustainable and the yield warning overly cautious. | ||
Institutions are reducing their holdings and the put/call ratio is elevated at 5.50, a bearish ownership and options signal. Key risks | Institutional holder-change score recovers above 4 from 1.1 and the put/call ratio falls below 2. | →Stable |
| CounterA high put/call ratio on an illiquid small-cap can be driven by a few hedging positions and not reflect broad bearishness. | ||
The price is below its 200-day average but the average is still rising, a pullback in an uptrend, with earnings due in 2 days after a 2-beat, 2-miss record. Momentum breakdown | EPS surprise turns positive and price reclaims the 200-day average. | ↑Improving |
| CounterEarnings history is split evenly, so the binary event in 2 days could hit a stock with only 5.1% cushion to the stop. | ||
Quality is high at 7.5 out of 10, with 19% margins, free cash flow at 239% of net income and a Piotroski F-Score of 8/9.
↓DeterioratingQuality breakdown
- Expectation
- Piotroski F-Score holds at 7 or higher and cash conversion stays above 100%.
CounterREIT cash flow metrics ignore heavy depreciation and recurring capital spending, and high leverage (D/E 2.7) reduces the margin for error.
The price of $37.67 is 0.7% above the $37.40 analyst target, leaving no analyst-implied upside against 5.1% downside.
↓DeterioratingTargets
- Expectation
- Analysts raise the target above $41, restoring at least 10% of upside.
CounterTargets for REITs tend to follow price, so a new higher target may come only after the stock has already moved up.
A leverage penalty applies at a debt-to-equity of 2.7, and the dividend is flagged as a high-yield-but-unsafe yield trap.
→StableBear case
- Expectation
- Debt-to-equity falls below 2.0 and the dividend is held flat or raised.
CounterHealthcare REIT leases are long-dated and stable, so leverage may be sustainable and the yield warning overly cautious.
Institutions are reducing their holdings and the put/call ratio is elevated at 5.50, a bearish ownership and options signal.
→StableKey risks
- Expectation
- Institutional holder-change score recovers above 4 from 1.1 and the put/call ratio falls below 2.
CounterA high put/call ratio on an illiquid small-cap can be driven by a few hedging positions and not reflect broad bearishness.
The price is below its 200-day average but the average is still rising, a pullback in an uptrend, with earnings due in 2 days after a 2-beat, 2-miss record.
↑ImprovingMomentum breakdown
- Expectation
- EPS surprise turns positive and price reclaims the 200-day average.
CounterEarnings history is split evenly, so the binary event in 2 days could hit a stock with only 5.1% cushion to the stop.
Per-dimension breakdown
Quality
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.5 |
| ROA | 2.8 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 5.7 |
| Moat | 5.8 |
| Piotroski F | 8.9 |
- ▸Strong margins: 20%
- ▸Strong Piotroski F-Score: 8/9
Growth
4.3/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.6 |
| EPS growth | 6.1 |
Momentum
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.5 |
| Volume | 1.6 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.0 |
| Analyst rating | 5.9 |
| Price target | 5.5 |
- ▸LLM news sentiment: +0.40 (n=1)
- ▸Light analyst coverage (1.0) — signal dampened
Insider
3.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 1.1 |
| notable moves | 3.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions reducing
Peer rank
3.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.8 |
| quality rank | 7.0 |
| growth rank | 2.0 |
- ▸Superior ROE vs peers
Technical
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.7 |
| 52w position | 7.1 |
Risk (lower is worse)
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.4 |
| days to cover | 8.9 |
| volatility | 5.5 |
| put call | 1.1 |
| implied vol | 5.0 |
| beta | 7.9 |
| debt equity | 2.1 |
- ▸Elevated put/call: 1.83
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 9.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 7.0 |
| dividend safety | 5.5 |
| news activity | 5.0 |
- ▸Estimates up 77.8% (30d)
- ▸Earnings concerns: 2B/2M
- ▸Dividend: 7.8%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:6.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:114d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-2.0=NEGATIVE
Warning (1)
- DEATH_CROSS:momentum=6.5>=5.0 recovering
Reward-to-Risk
-2.01
Upside
-12.3%
Downside
6.1%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 56
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $0.5B<$5B
Investment implication
The F-path SELL output reflects an overall score of 2.6 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Quality at 7.2) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-2.0=NEGATIVE) reinforce the read. Current asymmetry R:R is -2.01 — supplementary context, not the trigger for this path.
The strongest dimensions are Quality at 7.2, Momentum at 6.5, and Sentiment at 6.1; the weakest are Technical at 2.6, Insider at 3.0, and Peer rank at 3.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -2.01 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Quality Healthcare Reit
Trip ifPiotroski F-Score falls below 6 from the current 8.
- P2Analyst Target Reached
Trip ifPrice falls more than 5.1% to the $33.46 stop level.
- P3Leverage And Yield Trap Risk
Trip ifDebt-to-equity exceeds 3.5 from the current 2.7 or the dividend is cut by more than 20%.
- P4Institutions Reducing And Hedging
Trip ifPut/call ratio exceeds 8 from the current 5.50.
- P5Pullback In Uptrend Before Earnings
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.